C H J van Eijck
Overview
Explore the profile of C H J van Eijck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M, et al.
BMC Cancer
. 2025 Feb;
25(1):299.
PMID: 39972248
Background: The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a...
2.
Rangelova E, Stoop T, van Ramshorst T, Ali M, van Bodegraven E, Javed A, et al.
Ann Oncol
. 2025 Jan;
PMID: 39814200
Background: Left-sided pancreatic cancer is associated with worse overall survival (OS) compared with right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with resectable pancreatic...
3.
Gehrels A, Wagner A, Besselink M, Verhoeven R, van Eijck C, van Laarhoven H, et al.
Eur J Cancer
. 2024 May;
206:114117.
PMID: 38781719
Introduction: Sex and gender are modulators of health and disease and may have impact on treatment allocation and survival in patients with cancer. In this study, we analyzed the impact...
4.
Giaccherini M, Giaccherini M, Rende M, Gentiluomo M, Gentiluomo M, Corradi C, et al.
Mutagenesis
. 2024 Apr;
PMID: 38606763
Pleiotropic variants (i.e., genetic polymorphisms influencing more than one phenotype) are often associated with cancer risk. A scan of pleiotropic variants was successfully conducted ten years ago in relation to...
5.
Aziz M, Saida L, van Eijck C, Mustafa D
Pancreatology
. 2023 Nov;
24(1):62-65.
PMID: 37957065
Background And Objective: Pancreatic ductal adenocarcinoma (PDAC) is known for its unfavorable prognosis. Gaining insights into the molecular mechanisms that contribute to its progression is crucial for developing effective therapies....
6.
van Dam J, Verkolf E, Dekker E, Bonsing B, Bratlie S, Brosens L, et al.
BMC Cancer
. 2023 Aug;
23(1):728.
PMID: 37550634
Background: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant...
7.
Doppenberg D, Besselink M, van Eijck C, Intven M, Koerkamp B, Kazemier G, et al.
BMC Cancer
. 2023 Jan;
23(1):70.
PMID: 36670370
No abstract available.
8.
Doppenberg D, Besselink M, van Eijck C, Intven M, Koerkamp B, Kazemier G, et al.
BMC Cancer
. 2022 Dec;
22(1):1363.
PMID: 36581914
Background: Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently treated...
9.
Stingl C, Lau S, van der Burg S, Aerts J, van Eijck C, Luider T
Data Brief
. 2022 Aug;
44:108490.
PMID: 35959468
The data described was acquired as part of a clinical study with the aim to investigate the potential of tumor-reactive T-cell response as response to vaccination of pancreatic cancer patients...
10.
Lau S, Klaase L, Vink M, Dumas J, Bezemer K, van Krimpen A, et al.
Eur J Cancer
. 2022 May;
169:20-31.
PMID: 35490565
Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis even after curative resection. Responses to immunotherapy are rare and related to inadequate T-cell priming. We previously demonstrated the...